{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T06:51:08Z","timestamp":1790319068372,"version":"4.1.0"},"reference-count":21,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2017,4,26]],"date-time":"2017-04-26T00:00:00Z","timestamp":1493164800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100007705","name":"Astellas Pharma Global Development","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007705","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Arthritis &amp; Rheumatology"],"published-print":{"date-parts":[[2017,5]]},"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>To evaluate the efficacy and safety of orally administered once\u2010daily peficitinib in combination with limited conventional synthetic disease\u2010modifying antirheumatic drugs (csDMARDs) in patients with moderate\u2010to\u2010severe rheumatoid arthritis (RA).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>In this randomized, double\u2010blind, phase IIb trial, patients with RA (n\u2009=\u2009289) were treated with peficitinib 25 mg, 50 mg, 100 mg, or 150 mg or matching placebo once daily for 12 weeks. The primary end point was the percentage of patients who met the American College of Rheumatology 20% improvement criteria (achieved an ACR20 response) at week 12.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>ACR20 response rates at week 12 were 22.0%, 36.8%, 48.3% (<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.05), 56.3% (<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.01), and 29.4% in the peficitinib 25 mg, 50 mg, 100 mg, 150 mg, and placebo groups, respectively. Patients in the peficitinib 100 mg and 150 mg groups achieved a rapid and statistically significant ACR20 response compared with those in the placebo group (<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.05), reaching statistical significance by week 2. Overall, the incidence of adverse events (AEs) was similar between patients receiving peficitinib and those receiving placebo. The most common AEs were upper respiratory tract infection (5% [n\u2009=\u200915]), nausea (4% [n\u2009=\u200912]), and urinary tract infection (4% [n\u2009=\u200910]). There was 1 case of herpes zoster in the placebo group, and 1 serious infection (limb abscess) in the peficitinib 25 mg group. There were no incidences of grade 2 or higher neutropenia or lymphopenia.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>In patients with moderate\u2010to\u2010severe RA, orally administered once\u2010daily peficitinib in combination with limited csDMARDs resulted in a dose\u2010dependent ACR20 response rate over 12 weeks with satisfactory tolerability.<\/jats:p><\/jats:sec>","DOI":"10.1002\/art.40054","type":"journal-article","created":{"date-parts":[[2017,1,24]],"date-time":"2017-01-24T14:12:42Z","timestamp":1485267162000},"page":"932-942","source":"Crossref","is-referenced-by-count":92,"title":["Peficitinib, a JAK Inhibitor, in Combination With Limited Conventional Synthetic Disease\u2010Modifying Antirheumatic Drugs in the Treatment of Moderate\u2010to\u2010Severe Rheumatoid Arthritis"],"prefix":"10.1002","volume":"69","author":[{"given":"Mark C.","family":"Genovese","sequence":"first","affiliation":[{"name":"Stanford University Palo Alto California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Greenwald","sequence":"additional","affiliation":[{"name":"Desert Medical Advances Palm Desert California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Codding","sequence":"additional","affiliation":[{"name":"Health Research of Oklahoma Oklahoma City"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Zubrzycka\u2010Sienkiewicz","sequence":"additional","affiliation":[{"name":"ARS Rheumatica Warsaw Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan J.","family":"Kivitz","sequence":"additional","affiliation":[{"name":"Altoona Center for Clinical Research Duncansville Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annie","family":"Wang","sequence":"additional","affiliation":[{"name":"Astellas Pharma Global Development Northbrook Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathyjo","family":"Shay","sequence":"additional","affiliation":[{"name":"Astellas Pharma Global Development Northbrook Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuegong","family":"Wang","sequence":"additional","affiliation":[{"name":"Astellas Pharma Global Development Northbrook Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jay P.","family":"Garg","sequence":"additional","affiliation":[{"name":"Astellas Pharma Global Development Northbrook Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario H.","family":"Cardiel","sequence":"additional","affiliation":[{"name":"Centro de Investigaci\u00f3n Cl\u00ednica de Morelia SC Morelia Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2017,4,26]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-202576"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)61424-X"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1109071"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.37816"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1112072"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1310476"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.13258"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2014-206478"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-210094"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1507247"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.14403"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.150613"},{"issue":"10","key":"e_1_2_8_14_1","article-title":"Filgotinib (GLPG0634), an oral JAK1 selective inhibitor is effective in combination with methotrexate in patients with active rheumatoid arthritis: results from a phase 2B dose ranging study [abstract]","volume":"67","author":"Westhovens R","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2015-eular.1758"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2015-208279"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780380602"},{"key":"e_1_2_8_18_1","article-title":"Peficitinib, a JAK inhibitor, in the treatment of moderate\u2010to\u2010severe rheumatoid arthritis in patients with an inadequate response to methotrexate","author":"Kivitz AJ","journal-title":"Arthritis Rheumatol"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780310302"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780350502"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780380107"},{"key":"e_1_2_8_22_1","unstructured":"MedDRA v14.0. URL:http:\/\/www.meddra.org\/."}],"container-title":["Arthritis &amp; Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fart.40054","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/art.40054","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/art.40054","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acrjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/art.40054","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T16:28:27Z","timestamp":1759940907000},"score":1,"resource":{"primary":{"URL":"https:\/\/acrjournals.onlinelibrary.wiley.com\/doi\/10.1002\/art.40054"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4,26]]},"references-count":21,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2017,5]]}},"alternative-id":["10.1002\/art.40054"],"URL":"https:\/\/doi.org\/10.1002\/art.40054","archive":["Portico"],"relation":{},"ISSN":["2326-5191","2326-5205"],"issn-type":[{"value":"2326-5191","type":"print"},{"value":"2326-5205","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,4,26]]}}}